Virpax Pharmaceuticals, Inc. (VRPX)
USD 0.31
(-7.52%)
USD 0.31
(-7.52%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -9.85 Million | -17.84 Million | -14.54 Million | -1.38 Million | -1.13 Million | -1.79 Million |
| Net Income | -15.18 Million | -21.65 Million | -12.05 Million | -4.33 Million | -3.3 Million | -2.64 Million |
| Depreciation & Amortization | - | - | - | - | - | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 544.77 Thousand | 745.03 Thousand | 974.23 Thousand | 1.47 Million | 678.14 Thousand | 384.95 Thousand |
| Change in working capital | 4.79 Million | 3.05 Million | -3.39 Million | 1.32 Million | 931.88 Thousand | 441.37 Thousand |
| Other non-cash items | 544.77 Thousand | 745.03 Thousand | -61.81 Thousand | 153.22 Thousand | 564.64 Thousand | 14.97 Thousand |
| Investing Cash Flow | - | - | - | - | - | - |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | - | - | 51.32 Million | 1.39 Million | 1.12 Million | 1.67 Million |
| Debt repayment | - | - | -1.6 Million | -21.22 Thousand | -500 Thousand | -554.76 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | 58.02 Million | 1.37 Million | 625 Thousand | 1.12 Million |
| Other Financing Activities | - | - | -5.08 Million | 42.44 Thousand | 1 Million | 554.76 Thousand |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | 599.43 Million | -993.1 Thousand | -686.77 Thousand | 1.34 Million | 923.94 Thousand | 454.5 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | -594.64 Million | 4.05 Million | -2.71 Million | -13.09 Thousand | 7947.00 | -13.13 Thousand |
| Cash at beginning of period | 18.99 Million | 36.84 Million | 54.79 Thousand | 41.53 Thousand | 48.37 Thousand | 173.24 Thousand |
| Cash at end of period | 9.14 Million | 18.99 Million | 36.84 Million | 54.79 Thousand | 41.53 Thousand | 48.37 Thousand |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -9.85 Million | -17.84 Million | 36.78 Million | 13.26 Thousand | -6834.00 | -124.87 Thousand |
| Free Cash Flow | -9.85 Million | -17.84 Million | -14.54 Million | -1.38 Million | -1.13 Million | -1.79 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -3.45 Million | -3.22 Million | -4.56 Million | -15.18 Million | -5.99 Million | -3.11 Million |
| Depreciation & Amortization | - | - | - | - | - | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 72.51 Thousand | 72.71 Thousand | -9634.00 | 544.77 Thousand | 195.56 Thousand | 218.25 Thousand |
| Change in working capital | 1.73 Million | -4.58 Million | 1.55 Million | 4.79 Million | 3.14 Million | 711.59 Thousand |
| Other non-cash items | 72.51 Thousand | 72.71 Thousand | -9634.00 | 544.77 Thousand | 195.56 Thousand | 218.25 Thousand |
| Investing Cash Flow | - | - | - | - | - | - |
| Investments in PPE | -3.00 | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 1.64 Million | 453.95 Thousand | - | - | - | - |
| Debt repayment | -148.42 Thousand | -453.95 Thousand | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 1.79 Million | - | - | - | - | - |
| Other Financing Activities | -601.79 Thousand | 453.95 Thousand | - | - | - | - |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | 1.18 Million | -304.18 Thousand | 599.23 Million | 599.43 Million | - | 352.53 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | 1.73 Million | -4.58 Million | 1.55 Million | -594.64 Million | 3.14 Million | 711.59 Thousand |
| Cash at beginning of period | 1.86 Million | 9.14 Million | 12.15 Million | 18.99 Million | 14.8 Million | 16.98 Million |
| Cash at end of period | 1.87 Million | 1.86 Million | 9.14 Million | 9.14 Million | 12.15 Million | 14.8 Million |
| Capital Expenditure | -3.00 | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | 4598.00 | -7.27 Million | -3.01 Million | -9.85 Million | -2.65 Million | -2.18 Million |
| Free Cash Flow | -1.64 Million | -7.72 Million | -3.01 Million | -9.85 Million | -2.65 Million | -2.18 Million |
PNBK
000066
RAFI
9017
ALLT
SCHAEFFLER